Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cardiac Pathways seeks approval for heart rhythm treatment:

This article was originally published in Clinica

Executive Summary

Cardiac Pathways has submitted an application for US approval of its cooled ablation system for treating ventricular tachycardia, a dangerously rapid heartbeat. The company is seeking expedited review for the device. The Chilli system works by burning channels in the heart with radiofrequency energy. Small tubes in the catheter deliver saline to cool the catheter tip. The system has been tested in clinical trials at 15 sites in the US involving 159 patients, most of whom had severe heart disease. Some 76% of those treated experienced complete eradication of VT after the procedure.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT080498

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel